The Medical Letter on Drugs and Therapeutics
Adjunctive Antipsychotics for Major Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Augmentation with a second-generation (atypical) antipsychotic is a treatment option for patients with major depressive disorder (MDD) whose symptoms persist following antidepressant monotherapy.1 Aripiprazole (Abilify), olanzapine in a fixed-dose combination with fluoxetine (Symbyax), and extended-release quetiapine (Seroquel XR) have been approved by the FDA for such use.

ARIPIPRAZOLE (Abilify) — In a randomized controlled trial, 362 patients with MDD who had not responded adequately to 8 weeks' treatment with a selective serotonin reuptake inhibitor (SSRI) or extended-release venlafaxine (Effexor XR, and others) were randomized to receive 6 weeks of adjunctive aripiprazole or placebo.Those who received adjunctive aripiprazole had significantly greater reductions in depression rating scores.2 A ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Adjunctive Antipsychotics for Major Depression
Article code: 1373b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian